Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cardiovascular Genetic Testing Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The size of the cardiovascular genetic testing market has seen swift expansion in recent years. This market is projected to expand from $3.93 billion in 2025 to $4.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. Factors contributing to its historical growth include a heightened understanding of hereditary cardiovascular conditions, an increase in molecular diagnostic capacities, reduced expenses associated with genetic sequencing, greater adoption of genetic counseling services, and intensified studies in cardiovascular genomics.
The cardiovascular genetic testing market size is projected for substantial expansion in the coming years, with an anticipated growth to $6.62 billion in 2030, reflecting a compound annual growth rate (CAGR) of 11.0%. This growth throughout the forecast period stems from factors such as the rising demand for precision medicine approaches, increased adoption of population-based genetic screening, the expansion of AI-driven variant interpretation, greater integration of genomics into clinical decision-making, and a heightened emphasis on preventive cardiovascular healthcare. Key developments expected during this period involve a surge in predictive genetic risk assessment, increased application of multigene panel testing, enhanced integration of bioinformatics and AI analytics, broader use of pharmacogenomic testing applications, and a stronger focus on personalized cardiovascular care.
Get A Free Sample Report With In-Depth Market Insights:
Cardiovascular Genetic Testing Market Growth Backed By Core Demand Fundamentals
The escalating occurrence of cardiovascular diseases is projected to drive the expansion of the cardiovascular genetic testing market in the coming period. Cardiovascular diseases (CVDs) constitute a range of conditions affecting the heart and blood vessels, including issues like heart attacks, strokes, and hypertension. The increasing prevalence of these diseases primarily stems from more sedentary lifestyles associated with urbanization, which contribute to obesity, hypertension, and metabolic disorders. This rising incidence of cardiovascular diseases stimulates demand for cardiovascular genetic testing, as early detection of genetic risks enables personalized prevention and treatment strategies, thereby lowering the likelihood of serious heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Consequently, the growing prevalence of cardiovascular disease is a significant impetus for the growth of the cardiovascular genetic testing market.
Cardiovascular Genetic Testing Market Segment Landscape And Growth Outlook
The cardiovascular genetic testing market covered in this report is segmented –
1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
Subsegments:
1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
Cardiovascular Genetic Testing Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to help guarantee medical necessity and a tailored approach to the patient’s specific health condition, thereby reducing unnecessary testing and costs. A clinician-ordered test constitutes a medical examination or diagnostic procedure requested by a healthcare professional to evaluate, monitor, or guide the management of a patient’s health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, launched a genetic test designed to assess inherited risk for eight cardiovascular conditions. This clinician-ordered test is available on a self-pay basis and evaluates genetic predisposition to eight conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development leveraged genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets the results and generates patient-friendly reports.
Cardiovascular Genetic Testing Market Industry Leaders And Competitive Landscape
Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.
View The Full Cardiovascular Genetic Testing Market Report:
Cardiovascular Genetic Testing Market Regional Analysis And Top Geography
North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model